AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$HAE

Haemonetics shares jump as CSL sets 2027 rollout of plasma devices

Haemonetics (HAE) shares rose 13% to $115.20 after CSL Limited (CSL) announced plans to roll out Haemonetics' plasma collection devices in US centers by 2027. The non-exclusive agreement allows CSL to use Haemonetics' devices and disposables, with full implementation details pending. Haemonetics' 2027 guidance remains unchanged, and updates on financial impact are expected in November 2026.

Original reporting
finance.yahoo.com
Published Oct 8, 2026, 3:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 3:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Haemonetics shares jump as CSL sets 2027 rollout of plasma devices — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$HAEBullishMed
01

Why it matters

The contract provides a multi‑year revenue stream and has already moved the stock sharply higher.

02

Market read

First report of a major supply deal that triggered a 13% intraday rally in Haemonetics, indicating material market impact.

03

What to watch

The agreement is non‑exclusive and CSL retains other suppliers, limiting Haemonetics' upside.

Relevance 8/10Novelty 8/10Timing: intraday today

Background

Haemonetics announced a non‑exclusive supply agreement with CSL Limited to equip US plasma collection centers with NexSys PCS devices and disposables through 2027.

Company-level read

Ticker impact

$HAEBullishHigh confidence
Context

Shares jumped over 13% after CSL announced rollout of Haemonetics' plasma devices to US centers.

Expected impact

likely further upside as rollout progresses and disposables generate recurring sales

Evidence & confidence

First‑report of a sizable contract with CSL, a major biotech, triggered a double‑digit price move, indicating market perception of material revenue impact.

Market effects

Sector

Strengthens the plasma‑collection equipment sector and may lift peers providing similar disposables.

Regional

Highlights US plasma collection market growth, benefiting domestic suppliers.

Global

Shows Australian biotech CSL expanding US footprint, a cross‑border partnership of interest to global investors.

Counterpoint

What could challenge this read

If rollout delays or regulatory hurdles arise, the initial price rally could reverse.

Key entities

  • company
    Haemonetics

    US‑listed provider of plasma collection devices.

  • company
    CSL Limited

    Australian biotech firm operating US plasma collection centers.

Read at source← All news

StoryHaemonetics secures CSL Plasma rollout of NexSys PCS devices across U.S. centers by end‑2027

Also covered by

6 outlets

Related articles

$HAEMedAI 8/10

Haemonetics Corp (HAE) (Q2 2027) Earnings Call Highlights: Raised Guidance and Expanded

Haemonetics Corp (HAE) reported Q2 2027 earnings, raising guidance but lowering operating margin expansion due to higher costs and investments. CEO Christopher Simon highlighted a multiyear growth opportunity with CSL, though margin contributions are expected in fiscal 2028. The company faces near-term pressures from elevated production and freight costs, with second-half margin expansion weighted toward Q4.

finance.yahoo.com
$HAEHighAI 8/10

Haemonetics Corporation Q2 2027 Earnings Call Summary

Haemonetics reported Q2 2027 plasma growth of 18%, driven by Persona PLUS adoption. CSL relationship expansion and FDA approval for PerQseal Elite were highlighted. Revenue guidance raised to 6-9%, but margin expansion lowered due to supply chain costs. Free cash flow conversion expected to exceed 80%.

finance.yahoo.com
$HAEMedAI 8/10

Haemonetics (HAE) Q2 2027 Earnings Call Transcript

Haemonetics reported Q2 2027 earnings, highlighting 6% organic growth in MedSurg and 14% in Apheresis. Key drivers include TEG 6s disposables, VASCADE products, and Persona PLUS adoption. The company raised its fiscal 2027 revenue guidance to 6%-9% organic growth and 8%-11% reported growth, citing strong first-half performance and increased visibility into customer commitments.

finance.yahoo.com
$HAEMed

Mizuho raises Haemonetics stock price target on plasma strength

Mizuho raised its price target for Haemonetics (HAE) to $165 from $140, citing 18% organic plasma growth and improved guidance. The stock has gained 151% over the past year. HAE reported Q2 earnings of $1.35 per share, beating estimates, with revenue up 9.3% YoY. BTIG also raised its target to $142. Investors note margin guidance concerns and growth spending.

investing.com
$HAEHighAI 8/10

BTIG raises Haemonetics stock price target to $142 on earnings beat

BTIG raised its price target on Haemonetics (HAE) to $142 from $130, maintaining a Buy rating. HAE's Q2 2027 revenue was $357.8M, up 9.3% YoY, beating estimates. Adjusted EPS was $1.35, exceeding expectations. All segments performed well, with Apheresis revenue at $204.8M. Adjusted gross margin increased to 61.9%. HAE raised fiscal 2027 revenue guidance but reduced adjusted EBIT margin expansion outlook.

investing.com